Neurogen Corp. (NRGN)
Scott Sacane of Furman Selz initiated coverage with a "buy" and added it to the firm's Recommended List. He said the Branford, Conn., company belongs to a small group of small-cap biotech companies (under $150 million) that have reduced both near-term development risk and long-term survival risk. He has a one-year price target of $14.